ARTBIO Revenue and Competitors
Estimated Revenue & Valuation
- ARTBIO's estimated annual revenue is currently $6.2M per year.
- ARTBIO's estimated revenue per employee is $155,000
Employee Data
- ARTBIO has 40 Employees.
- ARTBIO grew their employee count by 122% last year.
ARTBIO's People
Name | Title | Email/Phone |
---|---|---|
1 | Founding CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Chief Technical Officer | Reveal Email/Phone |
4 | VP, Clinical Development | Reveal Email/Phone |
5 | VP, Development Operations | Reveal Email/Phone |
6 | Head and SVP, Regulatory Affairs | Reveal Email/Phone |
7 | Head & SVP, Supply Chain and External Manufacturing | Reveal Email/Phone |
8 | SVP, Discovery | Reveal Email/Phone |
9 | Director, Finance | Reveal Email/Phone |
10 | Director, Drug Product Development and Manufacturing | Reveal Email/Phone |
ARTBIO Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is ARTBIO?
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.
keywords:N/AN/A
Total Funding
40
Number of Employees
$6.2M
Revenue (est)
122%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5M | 40 | -7% | N/A |
#2 | $3.1M | 40 | -20% | $22.5M |
#3 | $4.6M | 40 | 60% | N/A |
#4 | $6.2M | 40 | 67% | N/A |
#5 | $3.5M | 40 | 14% | N/A |